Broad Institute wins Patent Office ruling related to gene editing technique CRISPR

A U.S. Patent Office appeal board ruled in the ongoing dispute over control of patents on the gene-editing technique CRISPR, according to an MIT article.

The battle was brought by the University of California, Berkeley, when it challenged a dozen patents held by the Broad Institute, which is affiliated with Harvard and MIT, the article states.

According to a Broad Institute announcement: The Patent Trial and Appeal Board declared that the patents granted by USPTO to the Broad Institute, MIT and Harvard concerning CRISPR editing of eukaryotic genomes do not interfere with patent claims filed by UC Berkeley and the University of Vienna.

Over the next few years there will be many patents issued in the CRISPR field to many institutions. As of February, 2017 the USPTO has issued 50 patents with claims to CRISPR and/or Cas9, including a robust portfolio of 14 CRISPR patents to the Broad Institute, MIT and affiliated groups for inventions from Dr. Feng Zhang and the Zhang lab.

Dr. Zhang is scheduled to present the NIH NIBIB Lecture at the Biomedical Engineering Society 2017 Annual Meeting in Phoenix this October.

According to the Broad Institute announcement: We believe CRISPR should continue to be available to the global scientific community to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies. Consistent with our founding principle to propel the understanding and treatment of disease, Broad Institute and our partner organizations will continue to work to disseminate and share CRISPR genome editing tools to maximize public benefit, especially by continuing to make this transformative technology freely available to the worldwide academic community and for commercial and human therapeutic research through our inclusive innovation model.